Early fasting glucose measurements can predict later glycaemic response to once weekly dulaglutide.
Diabet Med
; 33(3): 391-4, 2016 Mar.
Article
en En
| MEDLINE
| ID: mdl-26179454
ABSTRACT
AIMS:
To assess whether early measures of fasting blood glucose predict later glycaemic response with once-weekly dulaglutide in patients with Type 2 diabetes mellitus.METHODS:
Post hoc analyses were conducted separately for two phase 3 studies (AWARD-5 and AWARD-1) in patients assigned to once-weekly dulaglutide. Week 2 fasting blood glucose was used as a predictor variable, and glycaemic treatment response was defined by HbA1c response based on a composite efficacy endpoint. The association between fasting blood glucose and the glycaemic response was analysed using chi-square tests.RESULTS:
There was a strong association between fasting blood glucose < 7.9 mmol/l at week 2 and achieving the HbA1c composite efficacy endpoint at week 26 (P < 0.01). Higher fasting blood glucose at week 2, however, did not predict absence of glycaemic response and requires further assessment.CONCLUSIONS:
Fasting blood glucose measured at 2 weeks may be an early and useful predictor of glycaemic response to once-weekly dulaglutide treatment.
Texto completo:
1
Colección:
01-internacional
Asunto principal:
Glucemia
/
Proteínas Recombinantes de Fusión
/
Fragmentos Fc de Inmunoglobulinas
/
Ayuno
/
Diabetes Mellitus Tipo 2
/
Péptidos Similares al Glucagón
/
Hipoglucemiantes
Tipo de estudio:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Female
/
Humans
/
Male
Idioma:
En
Revista:
Diabet Med
Asunto de la revista:
ENDOCRINOLOGIA
Año:
2016
Tipo del documento:
Article
País de afiliación:
Estados Unidos